Early detection of Parkinson's disease: unmet needs

Neurodegener Dis. 2008;5(3-4):137-9. doi: 10.1159/000113683. Epub 2008 Mar 6.

Abstract

A biomarker (biological marker) is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenetic processes or pharmacological responses to a therapeutic intervention. Expectations are high for the development of biomarkers since they make it possible to achieve a significant improvement in the diagnosis and classification of diseases like Parkinson's disease. As a surrogate marker for clinical studies, a biomarker can also be used to determine the efficacy of novel therapeutic interventions, such as neuroprotective strategies, and for monitoring the progress of the disease. Imaging techniques ((18)F-DOPA PET, (123)I-beta-CIT SPECT, MIBG scintigraphy, functional imaging), clinical tests (e.g. hyposmia, micrography, hyperechogenicity, apomorphine test), biochemical markers (e.g. alpha-synuclein and neuromelanin antibodies, oxidative and mitochondrial markers) and genetic tests for hereditary forms (PARK1 to PARK11) are evaluated for their suitability.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Early Diagnosis
  • Genetic Markers / genetics
  • Humans
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / genetics
  • Parkinson Disease / metabolism
  • Parkinson Disease / therapy

Substances

  • Biomarkers
  • Genetic Markers